LOGIN
Dronabinol effective in reducing central lesion pain from multiple sclerosis after 3-week treatment
September 2018
Dronabinol effective in reducing central lesion pain from multiple sclerosis after 3-week treatment
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
BMJ. 2004 Jul 31;329(7460):253Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
24 patients experiencing central lesion pain due to multiple sclerosis were randomly assigned to receive either dronabinol (maximum of 5mg twice per day) or placebo for 3 weeks. They then underwent a washout period of at least 3 weeks, and were crossed-over to receive the other intervention for 3 weeks. Patients were assessed on the median spontaneous pain intensity, radiating pain intensity, pain...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.